NIM Norwood Imm.

    RNS Number : 1185Z
  Norwood Immunology Ld
  16 July 2008
   
    NORWOOD IMMUNOLOGY LIMITED 

    Exclusive Evaluation Agreement Signed with MedImmune 

    Norwood Immunology Limited and its subsidiaries ('Norwood Immunology' or 'the Group') (AIM:NIM), the Group focused on stem cell
therapies, the rejuvenation and repair of the immune system and the development of virosomal vaccines, today announces that it has signed a
six month exclusive evaluation agreement for NIM's virosomal vaccine technology with MedImmune, a recognized leader in vaccine research and
development. 
    

Under the terms of this agreement, the Group has agreed to an exclusive collaboration period with MedImmune of six months in exchange for an
exclusivity fee and the reimbursement of certain costs associated with performing collaborative research programmes using certain MedImmune
vaccine candidates and the Group's virosome technology. 


    Richard Williams, CEO of Norwood Immunology, commented: "This agreement is indicative of the attractiveness of the Virosomal
Biological's adjuvanted virosome technology to major vaccine partners. We look to build on this second vaccine partnership with a major
pharmaceutical company and anticipate seeking partners for our preclinical package for Herpes Simplex Virus (HSV) in the second half of
2008." 



    For further information please contact:
    Richard Williams, Chief Executive Officer, Norwood Immunology Limited
    +44 (0)7860 295153
    Capel Irwin, Nicholas Marren, KBC Peel Hunt Ltd
    +44 (0)207 418 8900


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
AGRSFIFDISASEDW

Grafico Azioni Norwood Immunology (LSE:NIM)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Norwood Immunology (LSE:NIM)
Storico
Da Giu 2023 a Giu 2024